1908. Immunogenicity and Safety Profiles of Full (0.5 ml) Compared to Half (0.25 ml) Dose Inactivated Influenza Vaccines in Children 6–35 Months Old
Session: Poster Abstract Session: Vaccines: Influenza
Saturday, October 10, 2015
Room: Poster Hall


The licensed dose of inactivated influenza vaccines (IIV) in children 6–35 months (m) old varies by product and country (e.g. US: 0.25 ml; Canada: 0.25 or 0.5 ml).1,2 Historically, a 0.25 ml dose has been used to reduce reactogenicity, particularly fever and febrile convulsions, in young children, commonly observed for whole virus IV.3 However, split, subunit and recombinant IIV have much lower reactogenicity, thus questioning the rationale of using half dose in 6–35m-olds, who have lower immune responses compared to older children, for whom use of the full dose is standard practice.3–5


Here we compare the immunogenicity and safety profiles of GSK Vaccines' trivalent IIV (Dresden, Germany, IIV3-D; Québec, Canada, IIV3-Q), administered as 1 or 2 (depending on influenza vaccine priming status) half (0.25 ml) or full (0.5 ml) doses in children 6–35m old (Table 1).


The observed values of hemagglutination inhibition GMT, SCR and SPR after IIV3-D or IIV3-Q vaccination tended to increase when given as 0.5 ml vs 0.25 ml doses (Table 2), suggesting a clinically higher immunogenicity of the 0.5 ml dose.4,5

Acceptable safety profiles were observed for IIV3-D and IIV3-Q for both dosages, with no difference for fever (Table 3).4–6 0.5 ml doses of GSK Vaccines' quadrivalent IIV (Dresden, IIV4-D; Québec, IIV4-Q) were also well tolerated in 6–35m-olds.7–11

Among GSK Vaccines' IIV for use in 6–35m-olds, 0.5 ml IIV4-Q is approved in Canada and Mexico and none yet in the US.2,12


Increasing the IIV dose to 0.5 ml improves immunogenicity without increasing reactogenicity in 6–35m-olds.

Funding: GlaxoSmithKline Biologicals SA


1.     CDC. MMWR 2014;63:691

2.     www.phac-aspc.gc.ca/naci-ccni/flu-grippe-eng.php

3.     Skowronski et al. Pediatrics 2011;128:e276

4.     Pavia-Ruz et al. Hum Vaccin Immunother 2013;9:1978

5.     Langley et al. J Pediatric Infect Dis Soc 2012;1:55

6.     www.gsk-clinicalstudyregister.com; study ID: 111635

7.     Wang et al. PAS 2015

8.     Langley et al. J Pediatric Infect Dis Soc 2014;DOI:10.1093/jpids/piu098

9.     Langley et al. J Infect Dis 2013;208:544

10.  Domachowske et al. J Infect Dis 2013;207:1878

11.  Claeys et al. ESPID 2014

12.  www.cofepris.gob.mx/AS/Documents/RegistroSanitarioMedicamentos/Vacunas/Vacunas.pdf





Long Wang, MD, PhD1, Carine Claeys, MD2, Vijayalakshmi Chandrasekaran, MS1, Ping Li, PhD1, Bruce L. Innis, MD1 and Varsha K. Jain, MD, MPH1, (1)GSK Vaccines, King of Prussia, PA, (2)GSK Vaccines, Wavre, Belgium


L. Wang, GSK group of companies: Employee , Salary

C. Claeys, GSK group of companies: Employee and Shareholder , Salary

V. Chandrasekaran, GSK group of companies: Employee , Salary

P. Li, GSK group of companies: Employee and Shareholder , Salary

B. L. Innis, GSK group of companies: Employee and Shareholder , Salary

V. K. Jain, GSK group of companies: Employee and Shareholder , Salary

See more of: Vaccines: Influenza
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.